Cytochrome P450 2C19 Polymorphism and Antiplatelet Therapy. Who Should Really be Genotyped?

E-ISSN： 1873-4286|19|13|2489-2495

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.13, 2013-04, pp. : 2489-2495

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism

By Desta Z. Zhao X. Shin J-G. Flockhart D.A.

Clinical Pharmacokinetics, Vol. 41, Iss. 12, 2002-01 ,pp. : 913-958

Adis International

Access to resources Recommend Favorite

Cytochrome P450 2C19 (CYP2C19) genotype appears to affect the efficacy of omeprazole

Inpharma, Vol. 1, Iss. 1221, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Genetic Variations in Cytochrome P450 2C9 and 2C19: A Review

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 14, Iss. 1, 2017-01 ,pp. : 18-28

Bentham Science Publishers

Access to resources Recommend Favorite

Fatal intoxication cases: cytochrome P₄₅₀2D6 and 2C19 genotype distributions

By Zackrisson A. Holmgren P. Gladh A. Ahlner J. Lindblom B.

European Journal of Clinical Pharmacology, Vol. 60, Iss. 8, 2004-10 ,pp. : 547-552

Springer Publishing Company

Access to resources Recommend Favorite

Genotype–phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region

By Varshney Ekta Saha Nilanjan Tandon Monika Shrivastava Vikesh Ali Shakir

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 38, Iss. 4, 2013-12 ,pp. : 275-282

Springer Publishing Company

Access to resources Recommend Favorite